HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Objectives. The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship betwee...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2021/6684629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685929047883776 |
|---|---|
| author | Tamera J. Lillemoe Mara Rendi Michaela L. Tsai Monica Knaack Rina Yarosh Erin Grimm Barbara Susnik Janet Krueger Susan Olet Karen K. Swenson |
| author_facet | Tamera J. Lillemoe Mara Rendi Michaela L. Tsai Monica Knaack Rina Yarosh Erin Grimm Barbara Susnik Janet Krueger Susan Olet Karen K. Swenson |
| author_sort | Tamera J. Lillemoe |
| collection | DOAJ |
| description | Objectives. The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship between patterns of HER2 testing results and response to NAC. We evaluated clinicopathologic characteristics associated with RCB categories in HER2+ patients who underwent HER2-directed NAC. Methods. A retrospective chart review was conducted with Stage I–III HER2+ breast cancer cases following NAC and surgical resection. HER2 immunohistochemistry (IHC) staining and fluorescence in situ hybridization (FISH), histologic/clinical characteristics, hormone receptor status, and RCB scores (RCB-0, RCB-I, RCB-II, and RCB-III) were evaluated. Results. 64/151 (42.4%) patients with HER2+ disease had pathologic complete response (pCR). Tumors with suboptimal response (RCB-II and RCB-III) were more likely to demonstrate less than 100% HER2 IHC 3+ staining (p<0.0001), lower HER2 FISH copies (p<0.0001), and lower HER2/CEP17 ratios (p=0.0015) compared to RCB-I and RCB-II responses. Estrogen receptor classification using ≥10% versus ≥1% staining showed greater association with higher RCB categories. Conclusions. HER2+ characteristics show differing response to therapy despite all being categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores. |
| format | Article |
| id | doaj-art-bb78fc25820f448b871f0e9180395daa |
| institution | DOAJ |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-bb78fc25820f448b871f0e9180395daa2025-08-20T03:22:54ZengWileyInternational Journal of Breast Cancer2090-31702090-31892021-01-01202110.1155/2021/66846296684629HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast CancerTamera J. Lillemoe0Mara Rendi1Michaela L. Tsai2Monica Knaack3Rina Yarosh4Erin Grimm5Barbara Susnik6Janet Krueger7Susan Olet8Karen K. Swenson9Allina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health System, Virginia Piper Cancer Institute Clinical Research Program, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health System, Virginia Piper Cancer Institute Clinical Research Program, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health System, Virginia Piper Cancer Institute Clinical Research Program, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health Laboratory-Hospital Pathology Associates, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health System, Virginia Piper Cancer Institute Clinical Research Program, 800 East 28th Street, Minneapolis, MN 55407, USAAllina Health System, Research Informatics, 925 Chicago Avenue, Minneapolis, MN 55407, USAAllina Health System, Virginia Piper Cancer Institute Clinical Research Program, 800 East 28th Street, Minneapolis, MN 55407, USAObjectives. The response to HER2-targeted neoadjuvant chemotherapy (NAC) in HER2-positive (+) breast cancer can be quantified using residual cancer burden (RCB) pathologic evaluation to predict relapse free/overall survival. However, more information is needed to characterize the relationship between patterns of HER2 testing results and response to NAC. We evaluated clinicopathologic characteristics associated with RCB categories in HER2+ patients who underwent HER2-directed NAC. Methods. A retrospective chart review was conducted with Stage I–III HER2+ breast cancer cases following NAC and surgical resection. HER2 immunohistochemistry (IHC) staining and fluorescence in situ hybridization (FISH), histologic/clinical characteristics, hormone receptor status, and RCB scores (RCB-0, RCB-I, RCB-II, and RCB-III) were evaluated. Results. 64/151 (42.4%) patients with HER2+ disease had pathologic complete response (pCR). Tumors with suboptimal response (RCB-II and RCB-III) were more likely to demonstrate less than 100% HER2 IHC 3+ staining (p<0.0001), lower HER2 FISH copies (p<0.0001), and lower HER2/CEP17 ratios (p=0.0015) compared to RCB-I and RCB-II responses. Estrogen receptor classification using ≥10% versus ≥1% staining showed greater association with higher RCB categories. Conclusions. HER2+ characteristics show differing response to therapy despite all being categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores.http://dx.doi.org/10.1155/2021/6684629 |
| spellingShingle | Tamera J. Lillemoe Mara Rendi Michaela L. Tsai Monica Knaack Rina Yarosh Erin Grimm Barbara Susnik Janet Krueger Susan Olet Karen K. Swenson HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer International Journal of Breast Cancer |
| title | HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer |
| title_full | HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer |
| title_fullStr | HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer |
| title_full_unstemmed | HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer |
| title_short | HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer |
| title_sort | her2 testing characteristics can predict residual cancer burden following neoadjuvant chemotherapy in her2 positive breast cancer |
| url | http://dx.doi.org/10.1155/2021/6684629 |
| work_keys_str_mv | AT tamerajlillemoe her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT mararendi her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT michaelaltsai her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT monicaknaack her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT rinayarosh her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT eringrimm her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT barbarasusnik her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT janetkrueger her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT susanolet her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer AT karenkswenson her2testingcharacteristicscanpredictresidualcancerburdenfollowingneoadjuvantchemotherapyinher2positivebreastcancer |